.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Citi
US Army
AstraZeneca
Cipla
Federal Trade Commission
Cantor Fitzgerald
Fish and Richardson
Cerilliant
Moodys

Generated: December 16, 2017

DrugPatentWatch Database Preview

OSENI Drug Profile

« Back to Dashboard

Which patents cover Oseni, and when can generic versions of Oseni launch?

Oseni is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are ten patents protecting this drug.

This drug has two hundred and forty-six patent family members in forty-four countries and sixty-four supplementary protection certificates in twelve countries.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-001Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-006Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-002Jan 25, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-003Jan 25, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-001Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-002Jan 25, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-002Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-003Jan 25, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-006Jan 25, 2013RXYesNo► Subscribe► SubscribeYY► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-006Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OSENI

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-004Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-001Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-002Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-005Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-003Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-002Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-006Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-001Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-006Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-005Jan 25, 2013► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: OSENI

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,211,205 Pharmaceutical composition► Subscribe
6,172,090 Pharmaceutical composition► Subscribe
6,133,293 Pharmaceutical composition► Subscribe
7,906,523Dipeptidyl peptidase inhibitors► Subscribe
6,211,207 Pharmaceutical composition► Subscribe
6,911,459 Pharmaceutical composition► Subscribe
7,144,900Pharmaceutical composition► Subscribe
6,169,100 Pharmaceutical composition► Subscribe
6,599,923 Pharmaceutical composition► Subscribe
7,781,584Dipeptidyl peptidase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OSENI

Country Document Number Estimated Expiration
South Africa200905621► Subscribe
Hong Kong1033420► Subscribe
European Patent Office2433623► Subscribe
CroatiaP20080509► Subscribe
Japan2007314551► Subscribe
Australia723097► Subscribe
Canada2423025► Subscribe
Canada2179584► Subscribe
Luxembourg92374► Subscribe
Australia5603496► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: OSENI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1Finland► Subscribe
606Luxembourg► Subscribe91606, EXPIRES: 20210620
0861666/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
C/GB14/083United Kingdom► SubscribePRODUCT NAME: ALOGLIPTIN; REGISTERED: UK EU/1/13/844 20130923
C/GB07/009United Kingdom► SubscribeSPC/GB07/009: 20070126
2014 00065Denmark► SubscribePRODUCT NAME: LINAGLIPTIN; REG. NO/DATE: EU/1/11/707/001-011 20110824
2009 00045Denmark► Subscribe
2007 00001Denmark► Subscribe
1Finland► Subscribe
C0035France► SubscribePRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE IN FRANCE: EU/1/07/383/001 DU 20070321; REGISTRATION NO/DATE AT EEC: EU/1/07/383/001-018 DU 20070321
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Chubb
Novartis
Fuji
Queensland Health
US Department of Justice
Baxter
Merck
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot